GlassScriptPhysician profile
Marissa Bournique
NPI 1417332131
$5,352.86
in general payments reported to CMS, 2019-2025
29 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,101 · 2020: $481 · 2021: $871 · 2022: $219 · 2023: $831 · 2024: $287 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,462.06 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Cook Medical LLC | $661.01 | 2019-2021 | |
| Janssen Biotech, INC. | $500.38 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $348.07 | 2019-2022 | |
| Gilead Sciences, INC. | $275.14 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.53 | 2019-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $229.11 | 2019-2023 | Watchman Flx, Rezum Generator |
| Inspire Medical Systems, INC. | $183.56 | 2024-2025 | Inspire |
| Pfizer INC. | $181.48 | 2019-2023 | |
| Ambu INC. | $169.41 | 2021 | |
| Madrigal Pharmaceuticals | $139.79 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $124.55 | 2021 | |
| Erbe USA INC | $117.14 | 2019-2024 | |
| Celgene Corporation | $114.85 | 2019-2023 | Zeposia |
| Redhill Biopharma INC. | $106.89 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $94.95 | 2019 | |
| Concordia Pharmaceuticals INC. | $63.18 | 2019 | |
| Napo Pharmaceuticals INC | $63.18 | 2019 | |
| Novo Nordisk INC | $61.31 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Welch Allyn | $43.67 | 2021 | |
| Genzyme Corporation | $31.40 | 2023 | |
| Braintree Laboratories, INC. | $30.17 | 2023 | Suflave |
| Actelion Pharmaceuticals US, INC. | $23.34 | 2022 | |
| Amgen INC. | $19.83 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.83 | 2023 | |
| Echosens North America, INC. | $16.68 | 2022 | |
| Exact Sciences Corporation | $16.48 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.77 | 2023 | Gattex |
| Ucb, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Bournique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.